Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CASUAL-ECMO: Anticoagulation Strategies for ECMO Support
NCT06442267Phase 4Recruiting
- Sponsor
- Medical University of Vienna
- Start
- Jul 2024
- Primary completion
- Jan 2027
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of enoxaparin, argatroban in thromboembolism, sponsored by Medical University of Vienna. Started Jul 2024; status: recruiting.
02
Drugs
enoxaparinargatroban
03
Conditions
thromboembolism
Beyond the preview
Go deeper on NCT06442267.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06442267.